Petra Simic1,2, Jodie L Babitt3,4. 1. Nephrology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. psimic@mgh.harvard.edu. 2. Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. psimic@mgh.harvard.edu. 3. Nephrology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Babitt.jodie@mgh.harvard.edu. 4. Program in Membrane Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Babitt.jodie@mgh.harvard.edu.
Abstract
PURPOSE OF REVIEW: Fibroblast growth factor 23 (FGF23) is a bone- and bone marrow-derived hormone that is critical to maintain phosphate homeostasis. The principal actions of FGF23 are to reduce serum phosphate levels by decreasing kidney phosphate reabsorption and 1,25-dihydroxyvitamin D synthesis. FGF23 deficiency causes hyperphosphatemia and ectopic calcifications, while FGF23 excess causes hypophosphatemia and skeletal defects. Excess FGF23 also correlates with kidney disease, where it is associated with increased morbidity and mortality. Accordingly, FGF23 levels are tightly regulated, but the mechanisms remain incompletely understood. RECENT FINDINGS: In addition to bone mineral factors, additional factors including iron, erythropoietin, inflammation, energy, and metabolism regulate FGF23. All these factors affect Fgf23 expression, while some also regulate FGF23 protein cleavage. Conversely, FGF23 may have a functional role in regulating these biologic processes. Understanding the bi-directional relationship between FGF23 and non-bone mineral factors is providing new insights into FGF23 regulation and function.
PURPOSE OF REVIEW: Fibroblast growth factor 23 (FGF23) is a bone- and bone marrow-derived hormone that is critical to maintain phosphate homeostasis. The principal actions of FGF23 are to reduce serum phosphate levels by decreasing kidney phosphate reabsorption and 1,25-dihydroxyvitamin D synthesis. FGF23 deficiency causes hyperphosphatemia and ectopic calcifications, while FGF23 excess causes hypophosphatemia and skeletal defects. Excess FGF23 also correlates with kidney disease, where it is associated with increased morbidity and mortality. Accordingly, FGF23 levels are tightly regulated, but the mechanisms remain incompletely understood. RECENT FINDINGS: In addition to bone mineral factors, additional factors including iron, erythropoietin, inflammation, energy, and metabolism regulate FGF23. All these factors affect Fgf23 expression, while some also regulate FGF23 protein cleavage. Conversely, FGF23 may have a functional role in regulating these biologic processes. Understanding the bi-directional relationship between FGF23 and non-bone mineral factors is providing new insights into FGF23 regulation and function.
Authors: Aline L Resende; Rosilene M Elias; Myles Wolf; Luciene M Dos Reis; Fabiana G Graciolli; Geuza D Santos; Cristiane B Dias; Vanda Jorgetti; Viktoria Woronik; Rosa M A Moysés Journal: Cytokine Date: 2017-01-04 Impact factor: 3.861
Authors: Nobuaki Ito; Asiri R Wijenayaka; Matthew Prideaux; Masakazu Kogawa; Renee T Ormsby; Andreas Evdokiou; Lynda F Bonewald; David M Findlay; Gerald J Atkins Journal: Mol Cell Endocrinol Date: 2014-10-16 Impact factor: 4.102
Authors: Julia J Scialla; Huiliang Xie; Mahboob Rahman; Amanda Hyre Anderson; Tamara Isakova; Akinlolu Ojo; Xiaoming Zhang; Lisa Nessel; Takayuki Hamano; Juan E Grunwald; Dominic S Raj; Wei Yang; Jiang He; James P Lash; Alan S Go; John W Kusek; Harold Feldman; Myles Wolf Journal: J Am Soc Nephrol Date: 2013-10-24 Impact factor: 10.121
Authors: Ludmilla Bär; Martina Feger; Abul Fajol; Lars-Oliver Klotz; Shufei Zeng; Florian Lang; Berthold Hocher; Michael Föller Journal: Proc Natl Acad Sci U S A Date: 2018-05-14 Impact factor: 11.205
Authors: Petra Loid; Helena Hauta-Alus; Outi Mäkitie; Per Magnusson; Riikka E Mäkitie Journal: Front Endocrinol (Lausanne) Date: 2022-09-08 Impact factor: 6.055